Pneumococcal Vaccine Market To Reach $15.53 Billion by 2035

Pneumococcal vaccine market was valued at $8.90 billion in 2025 and is projected to reach $15.53 billion by 2035, growing at a CAGR of 5.7% during the forecast period (2026–2035). The rising global burden of pneumococcal diseases and increasing immunization coverage are key macro drivers supporting market growth. According to the World Health Organization, pneumococcal disease remains one of the leading causes of vaccine-preventable deaths among children under five, contributing to hundreds of thousands of fatalities annually. Expanding government-led immunization programs and global health initiatives are significantly increasing vaccine uptake. Pneumococcal vaccines play a critical role in preventing invasive diseases such as pneumonia, meningitis, and sepsis, particularly among infants and elderly populations. Increasing awareness regarding adult vaccination and the expansion of national immunization schedules are further strengthening market demand globally.

Browse the full report description of “Pneumococcal Vaccine Market Size, Share & Trends Analysis Report, By Vaccine Type (Pneumococcal Conjugate Vaccines (PCVs), Pneumococcal Polysaccharide Vaccines (PPSVs)), By Technology Platform (Conjugate Vaccine Technology, Polysaccharide Vaccine Technology), By End User (Hospitals, Pediatric Clinics, Adult Vaccination Centers, Public Immunization Programs, Pharmacies / Retail Vaccination), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/pneumococcal-vaccine-market-share

Rising Immunization Programs Driving Market Expansion

The growth of large-scale immunization initiatives is significantly boosting the demand for pneumococcal vaccines. According to UNICEF, global vaccine procurement and distribution programs have expanded substantially, with millions of doses supplied annually to low- and middle-income countries. Public immunization programs represent a major end-user segment, supported by government funding and international alliances. Increasing inclusion of pneumococcal conjugate vaccines (PCVs) in national immunization schedules across emerging economies is driving strong adoption rates. Additionally, healthcare systems are prioritizing vaccination among high-risk groups, including elderly populations and individuals with chronic diseases, further accelerating demand.

Technological Advancements and Product Innovation

Continuous innovation in vaccine technology is enhancing market growth. Conjugate vaccine technology is gaining significant traction due to its superior immunogenicity and long-lasting protection compared to traditional polysaccharide vaccines. Manufacturers are focusing on developing higher-valency vaccines that provide broader serotype coverage. Increasing investments in R&D and advancements in bioconjugation technologies are enabling the development of next-generation pneumococcal vaccines with improved efficacy and safety profiles.

Key Leaders Transforming the Pneumococcal Vaccine Market
The key players in the pneumococcal vaccine market include Pfizer Inc., Merck & Co., Inc., GSK plc, Serum Institute of India Pvt. Ltd., and Walvax Biotechnology Co., Ltd., among others. These companies are focusing on product innovation, strategic partnerships, and geographic expansion to strengthen their market position.

• In March 2026, Pfizer Inc. and Valneva SE (USA & France) announced positive Phase 3 results from the VALOR clinical trial for their investigational Lyme disease vaccine candidate PF-07307405 (LB6V). The vaccine demonstrated over 70% efficacy in preventing Lyme disease among individuals aged five years and above and was well tolerated with no major safety concerns. The companies plan to proceed with regulatory submissions, strengthening their vaccine pipeline and expanding their presence in the global infectious disease vaccine market.
• In September 2025, Merck & Co., Inc. (USA) announced positive Phase 3 STRIDE-13 trial results for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine), demonstrating strong immune responses in children and adolescents at increased risk of pneumococcal disease. The vaccine showed immunogenicity across all 21 serotypes, with superior responses compared to PPSV23 for unique serotypes and comparable safety profiles. These results strengthen Merck’s pneumococcal vaccine portfolio, with plans to submit data to global regulatory authorities for expanded approvals.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
• Vaccine Type
• Technology Platform
• End User
• Regions Covered-
• North America
• Europe
• Asia-Pacific
• Rest of the World
• Competitive Landscape – Pfizer Inc., Merck & Co., Inc., GSK plc, Serum Institute of India Pvt. Ltd., Walvax Biotechnology Co., Ltd., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Pneumococcal Vaccine Market Segmentation

By Vaccine Type

• Pneumococcal Conjugate Vaccines (PCVs)
• Pneumococcal Polysaccharide Vaccines (PPSVs)

By Technology Platform

• Conjugate Vaccine Technology
• Polysaccharide Vaccine Technology

By End User

• Hospitals
• Pediatric Clinics
• Adult Vaccination Centers
• Public Immunization Programs
• Pharmacies / Retail Vaccination

Global Pneumococcal Vaccine Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/pneumococcal-vaccine-market-share